- Home
- VNDA vs OPRX Comparison
VNDA vs OPRX Comparison
Compare VNDA & OPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNDA
- OPRX
- Stock Information
- Founded
- VNDA 2002
- OPRX 2006
- Country
- VNDA United States
- OPRX United States
- Employees
- VNDA N/A
- OPRX N/A
- Industry
- VNDA Biotechnology: Pharmaceutical Preparations
- OPRX Business Services
- Sector
- VNDA Health Care
- OPRX Consumer Discretionary
- Exchange
- VNDA Nasdaq
- OPRX Nasdaq
- Market Cap
- VNDA 249.4M
- OPRX 234.9M
- IPO Year
- VNDA 2006
- OPRX N/A
- Fundamental
- Price
- VNDA $4.75
- OPRX $17.25
- Analyst Decision
- VNDA Strong Buy
- OPRX Buy
- Analyst Count
- VNDA 2
- OPRX 8
- Target Price
- VNDA $16.50
- OPRX $11.81
- AVG Volume (30 Days)
- VNDA 551.9K
- OPRX 436.8K
- Earning Date
- VNDA 07-31-2025
- OPRX 08-07-2025
- Dividend Yield
- VNDA N/A
- OPRX N/A
- EPS Growth
- VNDA N/A
- OPRX N/A
- EPS
- VNDA N/A
- OPRX N/A
- Revenue
- VNDA $203,467,000.00
- OPRX $104,748,000.00
- Revenue This Year
- VNDA $16.86
- OPRX $14.44
- Revenue Next Year
- VNDA $39.78
- OPRX $10.63
- P/E Ratio
- VNDA N/A
- OPRX N/A
- Revenue Growth
- VNDA 11.78
- OPRX 25.89
- 52 Week Low
- VNDA $3.81
- OPRX $3.78
- 52 Week High
- VNDA $5.55
- OPRX $18.22
- Technical
- Relative Strength Index (RSI)
- VNDA 60.39
- OPRX 62.81
- Support Level
- VNDA $4.47
- OPRX $15.10
- Resistance Level
- VNDA $4.88
- OPRX $17.73
- Average True Range (ATR)
- VNDA 0.16
- OPRX 1.29
- MACD
- VNDA 0.05
- OPRX 0.11
- Stochastic Oscillator
- VNDA 82.43
- OPRX 84.30
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
About OPRX OptimizeRx Corporation
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.